Azalea Therapeutics Secures $82 Million in Seed and Series A Financing for In Vivo Genomic Medicine Platform

Leila Ahmed North America Legal Chronicle
Tagged:

Wilson Sonsini Goodrich & Rosati has advised Azalea Therapeutics on the transaction. Azalea Therapeutics, a biotechnology company specializing in precision genomic medicines delivered in vivo, has…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Leila Ahmed

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here